C12N 2502/50
Invertebrate cells
Official title: invertebrate cells
C12N2502/50 (Invertebrate cells) appears on 21 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 21
- Published applications
- 24
- Assignees
- 12
- Inventors
- 26
- Latest grant
- 28 Sep 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 3 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 5 |
| 2004 | 1 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 2 | 0 |
| 2011 | 4 | 8 |
| 2012 | 7 | 3 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
By publication year.
Recent patents
- Compositions and methods for long-term in vitro culture of the syphilis spirochete28 Sep 2021US 11,130,937 B2Board of Regents, The University of Texas System
- In vitro production of a cell population using feeder cells13 May 2014US 8,722,401 B2Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Identification of antigenic peptides from multiple myeloma cells4 Dec 2012US 8,323,655 B2Janssen Pharmaceutica NV
- Identification of antigenic peptides from multiple myeloma cells4 Dec 2012US 8,323,965 B2Janssen Pharmaceutica NV
- Identification of antigenic peptides from multiple myeloma cells31 Jul 2012US 8,232,101 B2Janssen Pharmaceutica NV
- Cell supporting serum19 Mar 2020US 2020/0087616 A1Serucell Corporation
- Compositions and methods for long-term in vitro culture of the syphilis spirochete30 Jan 2020US 2020/0032201 A1Board of Regents, The University of Texas System
- Cell lines that are free of viral infection and methods for their production5 Apr 2018US 2018/0094236 A1Boyce Thompson Institute for Plant Research, Inc.
- Identification of antigenic peptides from multiple myeloma cells23 Feb 2012US 2012/0045466 A1Janssen Pharmaceutica NV
- Identification of antigenic peptides from multiple myeloma cells23 Feb 2012US 2012/0045829 A1Janssen Pharmaceutica NV
Most cited
By later US patents
- Antigen presenting system and methods for activation of T-cells27US 6,255,073 B1The Scripps Research Institute · 2001
- Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease22US 7,842,501 B2Ortho-McNeil Pharmaceutical, Inc. · 2010
- Synthetic antigen presenting matrix16US 6,461,867 B1The Scripps Research Institute · 2002
- Method for producing a synthetic antigen presenting transformed Drosophila cell15US 6,362,001 B1The Scripps Research Institute · 2002
- Antigen presenting system and methods for activation of T-cells14US 6,225,042 B1The Scripps Research Institute · 2001